Evaluating Zilovertamab Vedotin Plus R-CHOP as Frontline Therapy for Patients With DLBCL: waveLINE-010
Russell Gollard, MD, Optum Care Cancer Care, Las Vegas, Nevada, shares insights into the waveLINE-010 clinical trial evaluating the addition of zilovertamab vedotin to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, compared to R-CHOP alone among patients with diffuse large B-cell lymphoma (DLBCL) who have not yet received treatment.
The results of this analysis will determine the efficacy and safety of zilovertamab vedotin, a monoclonal antibody complexed to a conjugate, in addition to the standard of care, R-CHOP, for patients with DLBCL.
Dr Gollard stated, “We're hoping to be able to tailor therapy for patients with diffuse large B-cell lymphoma, where the treatments are excellent and there've been a lot of improvements over the years, but there still are long-term toxicities and there still are many patients who relapse.”
Transcript:
Hi, I'm Dr. Russell Gollard. I'm a medical oncologist. I work with Optum Care Cancer Care in Las Vegas, Nevada, where I am the Director of Medical Oncology. It's really great to be here at ASCO and I wanted to talk about the waveLINE-010 study.
This study looks at patients with diffuse large [B-cell] lymphoma. The study compares R-CHOP with zilovertamab vedotin, which is a monoclonal antibody complexed to a conjugate, and what it does is look at the efficacy long-term between these 2 treatment regimens.
We're hoping that this changes the standard of care for diffuse large cell lymphoma, and in addition, decreases some of the toxicity associated with vincristine, which is a long time part of the R-CHOP therapy. We're hoping to be able to tailor therapy for patients with diffuse large cell lymphoma, where the treatments are excellent and there've been a lot of improvements over the years, but there still are long-term toxicities and there still are many patients who relapse. By using this new antibody drug conjugate, in place of vincristine, we're hoping to increase efficacy and in addition to that, to decrease toxicity.
This study will involve over 100 centers throughout the world, so it truly is an international study and patients will be followed over the next 6 to 8 years before the study finally accrues to maturity. We are really excited about this study and we're particularly excited to be involved.
Source:
Gollard R, Flynn J, Reddy N, et al. waveLINE-010: Zilovertamab vedotin plus R-CHP versus R-CHOP in untreated diffuse large B-cell lymphoma. Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract TPS7092.
